Filtered By:
Vaccination: Cervical Cancer Vaccine
Countries: Japan Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 56 results found since Jan 2013.
Corrigendum to "Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis" Vaccine 40(41) (2022) 5971-5996
Vaccine. 2023 Sep 1:S0264-410X(23)00787-9. doi: 10.1016/j.vaccine.2023.06.084. Online ahead of print.NO ABSTRACTPMID:37659892 | DOI:10.1016/j.vaccine.2023.06.084
Source: Cancer Control - September 2, 2023 Category: Cancer & Oncology Authors: Matthew Palmer Kota Katanoda Eiko Saito Cecilia Acuti Martellucci Shiori Tanaka Sayaka Ikeda Haruka Sakamoto Dorothy Machalek Julia M L Brotherton Jane S Hocking Source Type: research
Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030
Vaccine. 2023 Aug 1:S0264-410X(23)00854-X. doi: 10.1016/j.vaccine.2023.07.033. Online ahead of print.ABSTRACTBACKGROUND: The Immunization Agenda 2030 (IA2030) Impact Goal 1.1. aims to reduce the number of future deaths averted through immunization in the next decade. To estimate the potential impact of the aspirational coverage targets for IA2030, we developed an analytical framework and estimated the number of deaths averted due to an ambitious vaccination coverage scenario from 2021 to 2030 in 194 countries.METHOD: A demographic model was used to determine annual age-specific mortality estimates associated with vaccine c...
Source: Vaccine - August 3, 2023 Category: Allergy & Immunology Authors: Austin Carter William Msemburi So Yoon Sim Katy A M Gaythorpe Philipp Lambach Ann Lindstrand Raymond Hutubessy Source Type: research
Future perspectives of emerging novel drug targets and immunotherapies to control drug addiction
This article's main highlight is discussing the drug targets of SUDs and their associated mechanisms. Importantly, we have also discussed the scope of prophylactic measures to eliminate drug dependence.PMID:37099943 | DOI:10.1016/j.intimp.2023.110210
Source: International Immunopharmacology - April 26, 2023 Category: Allergy & Immunology Authors: Jonaid Ahmad Malik Javed N Agrewala Source Type: research
Patterns of HPV vaccine hesitancy among catch-up generations in Japan: A descriptive study
CONCLUSION: HPV vaccine awareness promotion strategies must be based on the characteristics of each group and the different distributions of sociodemographic factors.PMID:37024410 | DOI:10.1016/j.vaccine.2023.03.061
Source: Vaccine - April 6, 2023 Category: Allergy & Immunology Authors: Masaki Machida Shigeru Inoue Source Type: research
Establishment of Mono-scaled Benefit/Risk Analysis of HPV Vaccine
In this study, we developed a new method to calculate the benefits and risks of the HPV vaccines using disability-adjusted life year (DALY) as the mono-scaled weight for various benefits and risks relevant to the vaccines. We evaluated benefits as a gain of DALY values for cervical cancer and risks as the loss of DALY values for various adverse events by the vaccination. To calculate the loss of DALY values, we integrated all adverse events in the International Classification of Diseases chapters. The novel method reflected the men-women ratio of this epidemiological disease to a certain extent. Among the vaccinated women,...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - September 26, 2022 Category: Drugs & Pharmacology Authors: Katsura Tsukamoto Manami Inoue Hirohito Mori Naoki Matsumaru Source Type: research
Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis
This study was registered with PROSPERO: CRD42018117596.RESULTS: A total of 57759 women with normal cytology, 1766 ASCUS, 3764 LSIL, 2017 HSIL, 3130 CIN1, 1219 CIN2, 869 CIN3/AIS, and 4306 ICC (which included 1032 ICC-SCC, and 638 ICC-ADC) were tested for HPV. The summary estimate of any-HPV genotype in women with normal cytology was 15·6% (95% CI: 12·3-19·4) and in invasive cervical cancer (ICC) was 85·6% (80·7-89·8). The prevalence of HR-HPV was 86·0% (95% CI: 73·9-94·9) for cytological cases of HSIL, 76·9% (52·1-94·7) for histological cases of CIN3/AIS, and 75·7% (68·0-82·6) for ICC. In women with ICC, th...
Source: Cancer Control - September 9, 2022 Category: Cancer & Oncology Authors: Matthew Palmer Kota Katanoda Eiko Saito Cecilia Acuti Martellucci Shiori Tanaka Sayaka Ikeda Haruka Sakamoto Dorothy Machelek Julia Ml Brotherton Jane S Hocking Source Type: research
